TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6350625

Group type: EXPERIMENTAL
Intervention: Ceftazidime (0.5 gm. intramuscularly every 12 hours)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tobramycin (1 mg. per kg. intramuscularly every 8 hours)
Number of subjects: 51
Study: 30463425

Group type: EXPERIMENTAL
Intervention: Family Group Conferencing (FGC)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 328
Study: 29602567

Group type: EXPERIMENTAL
Intervention: Adenoviral keratoconjunctivitis (specifically adenovirus D species)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Adenoviral keratoconjunctivitis (non-adenovirus D species)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Adenoviral keratoconjunctivitis (all participants)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Adenoviral D species
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Non-United States origin participants
Number of subjects: 500
Study: 26912213

Group type: EXPERIMENTAL
Intervention: Benzylpiperazine (BZP) 200 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dexamphetamine (DEX) 20 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 24561644

Group type: EXPERIMENTAL
Intervention: Sevoflurane, Desflurane, Isoflurane
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Ventilation (IPPV)
Number of subjects: 59
Study: 22115971

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation program (MBSR)
Number of subjects: 300

Group type: COMPARATOR
Intervention: 10 Keys to Healthy Aging (control)
Number of subjects: 300
Study: 19515181

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg + Metformin 500 mg
Number of subjects: 1306

Group type: EXPERIMENTAL
Intervention: Saxagliptin 10 mg + Metformin 500 mg
Number of subjects: 1306

Group type: COMPARATOR
Intervention: Saxagliptin 10 mg
Number of subjects: 1306

Group type: COMPARATOR
Intervention: Metformin 500 mg
Number of subjects: 1306
Study: 17893379

Group type: EXPERIMENTAL
Intervention: 6-hour intensive education for physicians
Number of subjects: 102

Group type: COMPARATOR
Intervention: 2-hour traditional education for physicians
Number of subjects: 102
Study: 15545304

Group type: EXPERIMENTAL
Intervention: Fenoldopam (selective dopamine-1 receptor agonist)
Number of subjects: 0
Study: 11751780

Group type: EXPERIMENTAL
Intervention: Once-daily (od) vancomycin
Number of subjects: 121

Group type: COMPARATOR
Intervention: Twice-daily (bd) vancomycin
Number of subjects: 121
Study: 9679994

Group type: EXPERIMENTAL
Intervention: Tailored decision aid (booklet and audiotape)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General educational pamphlet
Number of subjects: 0
Study: 8082348

Group type: EXPERIMENTAL
Intervention: Reduced dose bolus alteplase (n = 96)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Full dose 100 mg/2 h alteplase (n = 44)
Number of subjects: 140
Study: 2530542

Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg b.d.
Number of subjects: 135

Group type: COMPARATOR
Intervention: Amoxicillin 1 g b.d.
Number of subjects: 135
Study: 31885300

Group type: EXPERIMENTAL
Intervention: Metronidazole combined with debridement gel
Number of subjects: 73

Group type: COMPARATOR
Intervention: Wet dressing therapy combined with silver sulfadiazine
Number of subjects: 73
Study: 31007001

Group type: EXPERIMENTAL
Intervention: Sufentanil combined with flurbiprofen axetil (SF group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sufentanil (S group)
Number of subjects: 140
Study: 27651354

Group type: EXPERIMENTAL
Intervention: Training with different exercises (three different exercises performed three times in two training sessions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Training with different exercises
Number of subjects: 60
Study: 25128910

Group type: EXPERIMENTAL
Intervention: eSET on Day 3
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: eSET on Day 5
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: eDET on Day 3
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: eDET on Day 5
Number of subjects: 199

Group type: COMPARATOR
Intervention: eSET
Number of subjects: 199

Group type: COMPARATOR
Intervention: eDET
Number of subjects: 199
Study: 23440713

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) treatment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PWS post-PDL
Number of subjects: 5

Group type: COMPARATOR
Intervention: Normal skin (N)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Untreated PWS (PWS)
Number of subjects: 5
Study: 22093121

Group type: EXPERIMENTAL
Intervention: Telephone coaching in addition to usual physiotherapy care
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual physiotherapy alone
Number of subjects: 30
Study: 19750263

Group type: EXPERIMENTAL
Intervention: Extra parenteral fluid therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Breast milk (Control group)
Number of subjects: 100
Study: 16469617

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (25, 50, or 100 mg)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 15302102

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Quinidine plus verapamil
Number of subjects: 848

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 848
Study: 11096147

Group type: EXPERIMENTAL
Intervention: Increased erythropoietin (Epo) at Hb levels falling below 10.5 g/dl (group A)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Increased erythropoietin (Epo) at Hb levels falling below 11.5 g/dl (group B)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Reduction in Epo dose at Hb levels above 12.0 g/dl (group C)
Number of subjects: 447
Study: 9415569

Group type: EXPERIMENTAL
Intervention: Ganciclovir (6 mg/kg once a day from day 1 to day 30, then 6 mg/kg once a day, Monday through Friday, until day 100)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ganciclovir (less than 7 weeks, mean duration 3 weeks)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ganciclovir (100 days prophylaxis)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ganciclovir (long-term use)
Number of subjects: 47
Study: 8347114

Group type: EXPERIMENTAL
Intervention: Anxiety mood induction procedure (MIP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation mood induction procedure (MIP)
Number of subjects: 0
Study: 2426669

Group type: EXPERIMENTAL
Intervention: VDD pacing (back‐up rate 40-50 bpm, upper rate 125-150 bpm)
Number of subjects: 44

Group type: COMPARATOR
Intervention: VVI pacing (70 bpm)
Number of subjects: 44
Study: 31375873

Group type: EXPERIMENTAL
Intervention: Concomitant transobturator tape (TOT) with anterior colporrhaphy
Number of subjects: 164

Group type: COMPARATOR
Intervention: Subvesical transobturator mesh (TOM)
Number of subjects: 164
Study: 28946532

Group type: EXPERIMENTAL
Intervention: Soft tissue mobilization (STM) three times a week
Number of subjects: 29

Group type: COMPARATOR
Intervention: Baseline home program (positioning, handling strategies, stretching and strengthening exercises, environmental adaptations)
Number of subjects: 29
Study: 27453226

Group type: EXPERIMENTAL
Intervention: de qi group
Number of subjects: 0

Group type: COMPARATOR
Intervention: control group
Number of subjects: 0
Study: 25556937

Group type: EXPERIMENTAL
Intervention: Organized screening (PSA testing every 2 years)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Opportunistic PSA testing
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Organized screening (biennial)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Organized biennial screening
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Opportunistic screening
Number of subjects: 10000
Study: 24359716

Group type: EXPERIMENTAL
Intervention: Health Lines (HL) intervention
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Health Lines intervention plus in-house monitoring (HLM)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 179
Study: 20537281

Group type: EXPERIMENTAL
Intervention: Biofilm-positive patients
Number of subjects: 51

Group type: COMPARATOR
Intervention: Biofilm-negative patients
Number of subjects: 51
Study: 19052242

Group type: EXPERIMENTAL
Intervention: Tilt table with integrated stepping device
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional tilt table
Number of subjects: 9
Study: 15883689

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid angioplasty with stenting (CAS)
Number of subjects: 0
Study: 12913723

Group type: EXPERIMENTAL
Intervention: 10 mg tadalafil
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 10099751

Group type: EXPERIMENTAL
Intervention: Women-held group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study: 8558201

Group type: EXPERIMENTAL
Intervention: Busulfan (BU) 7 mg/kg, Cyclophosphamide (CY) 50 mg/kg, Total-body irradiation (TBI) 12 Gy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional Cyclophosphamide (CY) 120 mg/kg and TBI (historical control)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Busulfan (BU) / Cyclophosphamide (CY) / Total-body irradiation (TBI)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: HLA genotypically matched marrow
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: All other marrow sources
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: RAEB-T
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: RAEB and CMML
Number of subjects: 31
Study: 1805277

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (50 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6337363

Group type: EXPERIMENTAL
Intervention: Objective laboratory tests indicating good prognosis (total serum protein >= 6 g%, SGOT <= 40 mU/ml, total serum bilirubin <= 0.6 mg%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Objective laboratory tests indicating good prognosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Objective laboratory tests indicating poor prognosis (presence of liver metastases)
Number of subjects: 0
Study: 30206071

Group type: EXPERIMENTAL
Intervention: Blinded independent central review
Number of subjects: 45688

Group type: COMPARATOR
Intervention: Local assessment
Number of subjects: 45688
Study: 27871576

Group type: EXPERIMENTAL
Intervention: High-dose remifentanil (effect site concentration of 4 ng/mL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low-dose remifentanil (effect site concentration of 1 ng/mL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen (800 mg)
Number of subjects: 120
Study: 24818763

Group type: EXPERIMENTAL
Intervention: ABT-450, ritonavir, ombitasvir, and dasabuvir with ribavirin (group 1)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: ABT-450, ritonavir, ombitasvir, and dasabuvir without ribavirin (group 2)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Comparison to telaprevir, peginterferon, and ribavirin
Number of subjects: 179
Study: 23339698

Group type: EXPERIMENTAL
Intervention: Calluna vulgaris (Cv) + UVB irradiated
Number of subjects: 50

Group type: COMPARATOR
Intervention: UVB irradiated
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cv + vehicle + UVB irradiated
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 50
Study: 20361466

Group type: EXPERIMENTAL
Intervention: Rituximab added to standard chemotherapy regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody-based therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted therapies
Number of subjects: 0
Study: 18234327

Group type: EXPERIMENTAL
Intervention: Tailored and targeted print-based PA interventions
Number of subjects: 280

Group type: COMPARATOR
Intervention: Wellness/control condition
Number of subjects: 280
Study: 15755830

Group type: EXPERIMENTAL
Intervention: Dark chocolate (100 g containing approximately 500 mg polyphenols)
Number of subjects: 15
Study: 12715224

Group type: EXPERIMENTAL
Intervention: Noh's operation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Roux-en-Y operation
Number of subjects: 90
Study: 10758046

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 19

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 19
Study: 8666447

Group type: EXPERIMENTAL
Intervention: Rough titanium abutments
Number of subjects: 6

Group type: COMPARATOR
Intervention: Smoother titanium abutments
Number of subjects: 6
Study: 1602637

Group type: EXPERIMENTAL
Intervention: 123I‐BMIPP
Number of subjects: 587
Study: 3933604

Group type: EXPERIMENTAL
Intervention: Photon therapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Low-dose 15 MeV neutrons (LDN)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: High-dose 15 MeV neutrons (HDN)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combination of photon and neutron therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 108
Study: 31184024

Group type: EXPERIMENTAL
Intervention: Antioxidant complex (Androdoz) for 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no antioxidant therapy)
Number of subjects: 80
Study: 30235745

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 60
Study: 26648173

Group type: EXPERIMENTAL
Intervention: Ambu AuraGain
Number of subjects: 100

Group type: COMPARATOR
Intervention: LMA Supreme
Number of subjects: 100
Study: 24817601

Group type: EXPERIMENTAL
Intervention: Oral imatinib at doses ranging between 300 and 800 mg
Number of subjects: 61
Study: 22335737

Group type: EXPERIMENTAL
Intervention: Semuloparin 20 mg once daily
Number of subjects: 3212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3212
Study: 20701468

Group type: EXPERIMENTAL
Intervention: Baseline C-reactive protein concentration
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Change in C-reactive protein concentration over gestation
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Elevated baseline C-reactive protein
Number of subjects: 255
Study: 17401042

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with lower anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with higher anxiety
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with lower anxiety
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with higher anxiety
Number of subjects: 0
Study: 16336365

Group type: EXPERIMENTAL
Intervention: Hands-and-knees positioning for at least 30 minutes over a 1-hour period during labor
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Hands-and-knees positioning
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (no hands-and-knees positioning)
Number of subjects: 147
Study: 10840425

Group type: EXPERIMENTAL
Intervention: Laser therapy (neodymium:YAG noncontact visual prostate ablation)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Transurethral prostatic resection
Number of subjects: 82
Study: 9356557

Group type: EXPERIMENTAL
Intervention: Personal therapy among patients living with family
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Personal therapy among patients living independently
Number of subjects: 151

Group type: COMPARATOR
Intervention: Family and supportive therapies among patients living with family
Number of subjects: 151

Group type: COMPARATOR
Intervention: Supportive therapy among patients living independently
Number of subjects: 151
Study: 8457085

Group type: EXPERIMENTAL
Intervention: Indobufen (oral antiplatelet agent)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 123
Study: 2880341

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 14
Study: 30033790

Group type: EXPERIMENTAL
Intervention: LectureKeepr (LK) - audio lecture content before class
Number of subjects: 100

Group type: COMPARATOR
Intervention: Written materials prepared by the professor - lecture content before class
Number of subjects: 100
Study: 26646803

Group type: EXPERIMENTAL
Intervention: Group 2 (G2) received 1 L of PEG in the day before SBCE and 1 L of PEG in the morning before SBCE (time between PEG and SBCE=4 h)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Group 1 (G1) received 2 L of PEG in the day before SBCE (time between PEG and SBCE=10 h)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both PEG regimens
Number of subjects: 57
Study: 24160904

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser treatment plus standard wound care
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo laser treatment plus standard wound care
Number of subjects: 39
Study: 21930549

Group type: EXPERIMENTAL
Intervention: LCPUFA-supplemented formula (N = 50)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control formula (N = 57)
Number of subjects: 107
Study: 18654867

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg (after dosage increase)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg with compliance enhancement tools
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (both dosages)
Number of subjects: 121
Study: 16339344

Group type: EXPERIMENTAL
Intervention: Cold water immersion (Water)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ice packs covering the upper legs (Packs)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ice vest (Vest)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No cooling (Control)
Number of subjects: 12
Study: 14501815

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate (GnRH agonist) for 3 months
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 71
Study: 10898414

Group type: EXPERIMENTAL
Intervention: Intracoronary radiation (gamma and beta emitters), maximum dose to the vessel wall was 30 to 55 Gy, followed by antiplatelet therapy (aspirin and either ticlopidine or clopidogrel for one month).
Number of subjects: 473

Group type: COMPARATOR
Intervention: Placebo group (no radiation), followed by antiplatelet therapy (aspirin and either ticlopidine or clopidogrel for one month).
Number of subjects: 473
Study: 9372677

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg/kg in 250 ml D5W
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (CON) 250 ml D5W
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 4
Study: 1401389

Group type: EXPERIMENTAL
Intervention: Problem-solving skills training (PSST)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Parent management training (PMT)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: PSST and PMT combined
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 97
Study: 2427393

Group type: EXPERIMENTAL
Intervention: Oral urokinase
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 101
Study: 30613009

Group type: EXPERIMENTAL
Intervention: Ronghuang granule (3 times a day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine treatment combined with traditional Chinese medicine retention enema (Control)
Number of subjects: 70
Study: 27418333

Group type: EXPERIMENTAL
Intervention: Low-concentration contrast agents (270 and 320 mg iodine/ml)
Number of subjects: 318

Group type: COMPARATOR
Intervention: High-concentration contrast agent (370 mg iodine/ml)
Number of subjects: 318
Study: 24328248

Group type: EXPERIMENTAL
Intervention: ACLS simulation scenario, 4-hour PowerPoint presentation, and demonstration on a static manikin
Number of subjects: 82

Group type: COMPARATOR
Intervention: PowerPoint presentation and demonstration only (Control)
Number of subjects: 82
Study: 22916818

Group type: COMPARATOR
Intervention: 20 g isolated yellow pea protein (P20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 10 g isolated yellow pea protein (P10)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 10 g isolated yellow pea fibre (F10)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 20 g isolated yellow pea fibre (F20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 39
Study: 20567163

Group type: EXPERIMENTAL
Intervention: Overlapping repair
Number of subjects: 149

Group type: COMPARATOR
Intervention: End-to-end repair
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 149
Study: 18678301

Group type: EXPERIMENTAL
Intervention: CP-778,875 2 mg/day
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: CP-778,875 0.5, 2, or 6 mg/day
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: CP-778,875 6 mg/day
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 19158541

Group type: EXPERIMENTAL
Intervention: High frequency TENS (100 Hz)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low frequency TENS (4 Hz)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 64
Study: 15750197

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 241
Study: 12027463

Group type: EXPERIMENTAL
Intervention: Immune modulation therapy (IMT) - 10 ml of citrated autologous blood administered by intra-muscular injection after exposure to UV light and oxidisation, 6 injections over 3 weeks followed by 3 weeks rest, with 2-4 courses depending on response.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Immune modulation therapy (IMT) - subgroup analysis for short distance claudicants
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo - subgroup analysis for short distance claudicants
Number of subjects: 70